Please use this identifier to cite or link to this item:
Title: Updates on the treatment of pterygium
Authors: Todorovic, Danijela
Vulović A.
Sreckovic M.
Jovanovic, Svetlana
Janicijevic K.
Todorovic Z.
Issue Date: 2016
Abstract: © 2016, University of Kragujevac, Faculty of Science. All rights reserved. Pterygium is an ocular disease characterised by the growth of fibrovascular conjunctiva on the cornea. It occurs more often in men, at an older age, and in individuals exposed to ultraviolet radiation. Surgical treatment is the primary treatment for pterygium and there are two common procedures for pterygium excision. In the first method, the head of the pterygium is separated from the corneal surface using a surgical blade. The second method is based on avulsion. Other approaches to excising the pterygium include the use of argon laser and excimer laser. Because of a high recurrence rate, adjuvant therapies, including radiotherapy, chemotherapy, and graft procedures, are used after pterygium excision. These procedures have become the standard long-term treatments for pterygium. Radiotherapy is based on beta irradiation. Chemotherapy includes the use of mitomycin C, 5-fluorouracil, bevacizumab, and loteprednol etabonate. Graft procedures include amniotic membrane grafts and conjunctival autografts. Many surgeons believe that using mitomycin C and conjunctival autografts provides the best outcomes in terms of recurrence, cosmetics and patient satisfaction.
Type: review
DOI: 10.1515/SJECR-2016-0012
ISSN: 1820-8665
SCOPUS: 2-s2.0-84988849424
Appears in Collections:Faculty of Medical Sciences, Kragujevac

Page views(s)




Files in This Item:
File Description SizeFormat 
10.1515-SJECR-2016-0012.pdf861.34 kBAdobe PDFThumbnail

This item is licensed under a Creative Commons License Creative Commons